Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists
Molecules, 21 marzo 2023

2) International Scientific Collaboration Is Needed to Bridge Science to Society: USERN2020 Consensus Statement
SN Comprehensive Clinical Medicine, 11 maggio 2021

3) Drug Repurposing on G Protein-Coupled Receptors Using a Computational Profiling Approach
Frontiers in Molecular Biosciences, 7 maggio 2021

4) Perspectives on High-Throughput Ligand/Protein Docking With Martini MD Simulations
Frontiers in Molecular Biosciences, 29 marzo 2021

5) Ligand binding free-energy calculations with funnel metadynamics
Nature Protocols, https://www.nature.com/articles/s41596-020-0342-4

6) Protein-ligand binding with the coarse-grained Martini model
Nature Communications, https://www.nature.com/articles/s41467-020-17437-5

7) Binding of the Anti-FIV Peptide C8 to Differently Charged Membrane Models: From First Docking to Membrane Tubulation
Frontiers in Chemistry, https://www.frontiersin.org/articles/10.3389/fchem.2020.00493/full

8) Bioinformatics and Biosimulations as Toolbox for Peptides and Peptidomimetics Design: Where Are We?
Frontiers in Molecular Biosciences, https://www.frontiersin.org/articles/10.3389/fmolb.2020.00066/full

9) Identification of Cysteinyl-leukotriene-receptor 1 antagonists as ligands for the bile acid receptor GPBAR1.
Biochemical Pharmacology, https://www.sciencedirect.com/science/article/abs/pii/S000629522030215X?via%3Dihub

10) GPBAR1 Activation by C6-Substituted Hyodeoxycholane Analogues Protect Against Colitis
ACS Medical Chemistry Letters, https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00636
Vittorio Limongelli
is currently collaborating with
Istituto Eulero (Rif. EI)
Via la Santa 1
6962 Lugano
Vittorio Limongelli
on behalf of
Istituto Eulero USI (Rif. EI)
is currently participating in the Research Group
Computational Pharmacology
as Group Leader [Rif. 55110]